MannKind and Blackstone Enter $500MM Financing Agreement
MannKind, a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, and funds managed by Blackstone have entered into an up to $500 million strategic financing agreement....
Read moreDetails










